Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-1-28
pubmed:abstractText
To investigate the prognostic value of cyclin E in relation to tumour growth pattern by analysing stage II primary breast cancers from premenopausal women not subjected to any further adjuvant treatment. To analyse the value of cyclin E as a predictor of tamoxifen response, by comparing untreated and treated patients with oestrogen receptor positive tumours.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1472-4146
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
61
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
184-91
pubmed:meshHeading
pubmed-meshheading:17483245-Adult, pubmed-meshheading:17483245-Antineoplastic Agents, Hormonal, pubmed-meshheading:17483245-Breast Neoplasms, pubmed-meshheading:17483245-Chemotherapy, Adjuvant, pubmed-meshheading:17483245-Cyclin E, pubmed-meshheading:17483245-Female, pubmed-meshheading:17483245-Follow-Up Studies, pubmed-meshheading:17483245-Humans, pubmed-meshheading:17483245-Lymphatic Metastasis, pubmed-meshheading:17483245-Middle Aged, pubmed-meshheading:17483245-Neoplasm Invasiveness, pubmed-meshheading:17483245-Neoplasm Proteins, pubmed-meshheading:17483245-Neoplasm Staging, pubmed-meshheading:17483245-Premenopause, pubmed-meshheading:17483245-Prognosis, pubmed-meshheading:17483245-Survival Analysis, pubmed-meshheading:17483245-Tamoxifen, pubmed-meshheading:17483245-Treatment Outcome, pubmed-meshheading:17483245-Tumor Markers, Biological
pubmed:year
2008
pubmed:articleTitle
Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
pubmed:affiliation
Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö, Sweden.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't